La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Imricor Medical Systems Dividendo

Dividendo criteri di controllo 0/6

Imricor Medical Systems non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	1.6%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-AU$0.08
Previsione del rendimento del dividendo a 3 anni	0%

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now

May 08

We Think Imricor Medical Systems (ASX:IMR) Needs To Drive Business Growth Carefully

Jan 24

What Is The Ownership Structure Like For Imricor Medical Systems, Inc. (ASX:IMR)?

Dec 02

What You Need To Know About Imricor Medical Systems, Inc.'s (ASX:IMR) Investor Composition

Aug 18

Analysts Expect Breakeven For Imricor Medical Systems, Inc. (ASX:IMR)

Jun 25

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di IMR siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di IMR siano aumentati.

Rendimento dei dividendi rispetto al mercato

Imricor Medical Systems Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di IMR rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (IMR)	n/a
Fondo del 25% del mercato (AU)	2.7%
Top 25% del mercato (AU)	6.3%
Media del settore (Medical Equipment)	1.6%
Previsione dell'analista in 3 anni (IMR)	0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di IMR rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di IMR rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di IMR per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché IMR non ha segnalato alcun pagamento.

Imricor Medical Systems Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

Imricor Medical Systems, Inc. to Report First Half, 2024 Results on Aug 28, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Independent Non-Executive Director recently bought AU$73k worth of stock

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now

Imricor Medical Systems, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Imricor Medical Systems, Inc., Annual General Meeting, May 15, 2024

Imricor Medical Systems, Inc. has completed a Follow-on Equity Offering in the amount of AUD 15.135297 million.

Insufficient new directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.12 loss in FY 2022)

Imricor Medical Systems, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024

New major risk - Revenue and earnings growth

Imricor Medical Systems, Inc. has filed a Follow-on Equity Offering in the amount of AUD 15 million.

First half 2023 earnings released: US$0.061 loss per share (vs US$0.068 loss in 1H 2022)

New major risk - Revenue and earnings growth

New major risk - Share price stability

Imricor Medical Systems, Inc. announced that it has received AUD 2.861607 million in funding

Imricor Medical Systems, Inc. to Report First Half, 2023 Results on Aug 23, 2023

Imricor Medical Systems, Inc. announced that it has received AUD 1.457143 million in funding

Does Imricor Medical Systems (ASX:IMR) Have A Healthy Balance Sheet?

New minor risk - Share price stability

Key Executive recently bought AU$195k worth of stock

Full year 2022 earnings: Revenues miss analyst expectations

Imricor Medical Systems, Inc. to Report Fiscal Year 2022 Results on Feb 22, 2023

Imricor Medical Systems, Inc. Receives IDE Approval from US FDA

Forecast to breakeven in 2025

Imricor Medical Systems, Inc. Receives the First of Two Required Approvals to Commence the Vision-MR Ablation of VT or VISABL-VT Clinical Trial

Imricor Medical Systems, Inc. announced that it expects to receive $5 million in funding from KAHR Foundation

President recently bought AU$76k worth of stock

President recently bought AU$76k worth of stock

Imricor Medical Systems, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Imricor Medical Systems, Inc. Submits Application for Approval to Commence A Real-Time iCMR-Guided Ventricular Tachycardia (VT) Ablation Clinical Trial

Imricor Medical Systems, Inc. announced that it has received AUD 2.947049 million in funding

First half 2022 earnings released: US$0.068 loss per share (vs US$0.079 loss in 1H 2021)

Imricor Medical Systems, Inc. to Report First Half, 2022 Results on Aug 25, 2022

Imricor Medical Systems, Inc. to Report Q4, 2022 Results on Jul 28, 2022

Here's Why Imricor Medical Systems (ASX:IMR) Must Use Its Cash Wisely

Imricor Medical Systems, Inc. Completes its Preclinical Work to Support Submission for Approval to Initiate VT Clinical Trial in Europe

Imricor Medical Systems, Inc., Annual General Meeting, May 03, 2022

Will Imricor Medical Systems (ASX:IMR) Spend Its Cash Wisely?

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 57%

Imricor Medical Systems, Inc. Announces Executive Changes

Consensus forecasts updated

Imricor Medical Systems, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022

Imricor Medical Systems, Inc. Files Application for an Investigational Device Exemption from US Food and Drug Administration

First half 2021 earnings released: US$0.079 loss per share (vs US$0.056 loss in 1H 2020)

No longer forecast to breakeven

Consensus forecasts updated

We're Hopeful That Imricor Medical Systems (ASX:IMR) Will Use Its Cash Wisely

Non-Executive Director has left the company

Imricor Medical Systems, Inc. Announces Board Changes

When Will Imricor Medical Systems, Inc. (ASX:IMR) Turn A Profit?

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.22 loss in FY 2019)

Revenue beats expectations

New 90-day low: AU$2.16

Imricor Medical Systems, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021

We Think Imricor Medical Systems (ASX:IMR) Needs To Drive Business Growth Carefully

Imricor Medical Systems, Inc. Appoints Gregg Stenzel as COO

Imricor Signs Supply and Sales Agreement with Osypka

What Is The Ownership Structure Like For Imricor Medical Systems, Inc. (ASX:IMR)?

Imricor Medical Systems, Inc. Signs New Purchase Agreement

New 90-day high: AU$2.78

Imricor Medical Systems, Inc. (ASX:IMR) signed an agreement to acquire Schleswig-Holstein University Medical Centre in Germany.

Imricor Medical Systems, Inc. to Commence Clinical Procedures After Receiving Ethics Committee Approval to Use Isuite Software

Imricor Awards National Institutes of Health Contract

Imricor Medical Systems, Inc. Signs Purchase Agreement with MUMC

New 90-day high: AU$2.30

Leipzig Heart Centre Signs Purchase Agreement with Imricor Medical Systems

New 90-day high - AU$2.15

Earnings released

What You Need To Know About Imricor Medical Systems, Inc.'s (ASX:IMR) Investor Composition

Imricor Medical Systems, Inc. to Report Fiscal Year 2020 Results on Aug 25, 2020